The GP Score, a Simplified Formula (Bioptic Gleason Score Times Prostate Specific Antigen) as a Predictor for Biochemical Failure after Prostatectomy in Prostate Cancer.

Gleason score Predictive factors Prostate cancer Prostate-specific antigen

Journal

Current urology
ISSN: 1661-7649
Titre abrégé: Curr Urol
Pays: United States
ID NLM: 101471188

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 13 07 2018
accepted: 10 09 2018
entrez: 4 10 2019
pubmed: 4 10 2019
medline: 4 10 2019
Statut: ppublish

Résumé

We used a new GP score (Gleason score multiplied by prostate-specific antigen) without the T stage as a predictive value for biochemical failure (BCF) after prostatectomy. We assessed 459 prostate cancer patients who underwent prostatectomies at our institution. Three sub-groups were defined in terms of D'Amico classification risk (low, intermediate, and high) and Gleason score (low, < 50; intermediate, 50-100; and high GP score, > 100). Risk factors for BCF were evaluated by multivariate analysis with a Cox hazard model. A log-rank test was used to compare the BCF rate in the 2 groups. There was nosignificant difference in the non-BCF rate between the lowrisk and low GP score subgroups or the intermediate risk andintermediate GP score subgroups. In contrast, the non-BCFrate of the high GP score subgroup (42.1%) was significantlylower than that of the high-risk subgroup (66.1%, log-rankp = 0.008). Based on multivariate analysis, a high GP score(p = 0.001; HR 3.78; 95%CI 1.95-7.35) was a significant independent risk factor for BCF after prostatectomy. The GP score, consisting of two absolute numbers, may be a valuable predictive factor for BCF after prostatectomy, especially in the high-risk failure group.

Identifiants

pubmed: 31579210
doi: 10.1159/000499298
pii: cur-0013-0025
pmc: PMC6771044
doi:

Types de publication

Journal Article

Langues

eng

Pagination

25-30

Informations de copyright

Copyright © 2019 by S. Karger AG, Basel.

Références

J Urol. 2010 Jul;184(1):114-9
pubmed: 20478578
Anticancer Res. 2014 Jun;34(6):3077-81
pubmed: 24922676
J Urol. 2005 Jun;173(6):1938-42
pubmed: 15879786
Jpn J Clin Oncol. 2011 Nov;41(11):1271-6
pubmed: 21971422
Urology. 2014 Dec;84(6):1329-34
pubmed: 25288575
Clin Oncol (R Coll Radiol). 2005 Dec;17(8):655-8
pubmed: 16372494
Cancer Chemother Rep. 1966 Mar;50(3):125-8
pubmed: 5948714
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Cancer. 2002 Jul 15;95(2):281-6
pubmed: 12124827
Strahlenther Onkol. 2007 Sep;183(9):490-6
pubmed: 17762923
Urol Oncol. 2004 Jul-Aug;22(4):295-9
pubmed: 15283886
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):69-75
pubmed: 20594769
Urol Int. 2015;95(4):452-6
pubmed: 26430904
J Urol. 2013 Nov;190(5):1728-34
pubmed: 23680307
Eur Urol. 2014 Jun;65(6):1171-7
pubmed: 23587869
Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):33-7
pubmed: 7505775
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):104-9
pubmed: 19286330
Radiother Oncol. 2013 Nov;109(2):211-6
pubmed: 23823866
Urology. 1997 Nov;50(5):733-9
pubmed: 9372884

Auteurs

Norihito Soga (N)

Department of Urology, Aichi Cancer Center Hospital, Nagoya.

Yuji Ogura (Y)

Department of Urology, Aichi Cancer Center Hospital, Nagoya.

Toshiaki Wakita (T)

Department of Urology, Wakita Clinic, Aichi.

Takumi Kageyama (T)

Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan.

Jun Furusawa (J)

Department of Urology, Aichi Cancer Center Hospital, Nagoya.

Classifications MeSH